Tucatinib bulk supplier for pharma manufacturers

Tucatinib 50 mg, 150 mg Suppliers & Bulk Manufacturers

Q: What is Tucatinib trade name?

The main trade name of Tucatinib is Tukysa, while generic brands include Tukavo in certain markets.

Q: What company makes Tucatinib?

Tucatinib (Tukysa) is manufactured and marketed by Seagen Inc. in collaboration with partners; generic versions like Tukavo are manufactured by companies such as Zydus Lifesciences in select regions.

Q: What is brand name of Tucatinib?

The brand names are Tukysa (USA, EU/UK) and Tukavo (India/emerging markets).

Available Forms: Tablets

Available Strengths: 50 mg, 150 mg

Reference Brands: Tukysa (USA, EU/UK), Tukavo (India)

Category: Oncology Cancer Care

Tucatinib is a Oncology Cancer Care product available as Tablets in strengths 50 mg, 150 mg. It corresponds to the reference brands Tukysa (USA, EU/UK), Tukavo (India). Verified GMP manufacturers and suppliers on PharmaTradz offer it in bulk for import worldwide, with regulatory documentation and dossier support available on request.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Product Description:

Tucatinib is an oral anticancer medication used in the treatment of HER2-positive cancers, particularly advanced or metastatic breast cancer. It is a small-molecule inhibitor that selectively targets the human epidermal growth factor receptor 2 (HER2), a protein that promotes the growth of certain cancer cells. By blocking HER2 signaling pathways, tucatinib helps slow down tumor growth and reduce the spread of cancer. This targeted mechanism allows it to work effectively while minimizing effects on other receptors compared to some older therapies.

Tucatinib is commonly used in combination with other anticancer medicines such as trastuzumab and capecitabine to improve treatment outcomes in patients who have previously received other HER2-directed therapies. One of the important advantages of tucatinib is its ability to provide benefits for patients whose cancer has spread to the brain, a condition that can be difficult to treat with many standard therapies. The medicine is administered orally in tablet form, making it convenient for ongoing treatment.

Overall, tucatinib represents an important advancement in targeted oncology therapy, offering an additional option for managing HER2-positive cancers and improving disease control in patients with advanced stages of the disease.

Tucatinib — third party manufacturing & bulk supply

Tucatinib 50 mg, 150 mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Tucatinib is supplied as Tablets — an oral solid dosage form, so the indicative MOQ is 200,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Tucatinib listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Tucatinib →

Back to Listing

Frequently Asked Questions

Tucatinib is used, in combination with trastuzumab and capecitabine, to treat adults with HER2-positive locally advanced or metastatic breast cancer, including patients with brain metastases, who have received prior anti-HER2 therapies. It is also approved in combination with trastuzumab for RAS wild-type, HER2-positive metastatic colorectal cancer after certain chemotherapy regimens.

Tucatinib is a small-molecule tyrosine kinase inhibitor that selectively targets the HER2 receptor inside cancer cells, blocking signaling pathways that promote tumor growth and survival.

The main trade name of Tucatinib is Tukysa, while generic brands include Tukavo in certain markets.

Tucatinib (Tukysa) is manufactured and marketed by Seagen Inc. in collaboration with partners; generic versions like Tukavo are manufactured by companies such as Zydus Lifesciences in select regions.

The generic name is Tucatinib.

The brand names are Tukysa (USA, EU/UK) and Tukavo (India/emerging markets).

Tucatinib is manufactured in facilities in the USA and other approved global sites; generic versions are produced in India and other emerging markets for regional distribution.